GlassScriptPhysician profile
Job B Mongare
NPI 1962463869
$16,929.27
in general payments reported to CMS, 2019-2025
48 companies · $2,940 in 2025
The $2,940 reported for 2025 was more than what 79% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,754 · 2020: $2,229 · 2021: $2,514 · 2022: $1,963 · 2023: $1,921 · 2024: $2,609 · 2025: $2,940.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,317 · Education: $152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,317.06 |
| Education | $152.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $1,779.23 | 2019-2025 | Mavenclad |
| Teva Pharmaceuticals USA, INC. | $1,624.91 | 2019-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Abbvie INC. | $1,604.32 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $1,414.47 | 2019-2025 | Nuplazid, Daybue |
| Mdd US Operations, LLC | $1,317.86 | 2019-2025 | Gocovri |
| Novartis Pharmaceuticals Corporation | $1,028.87 | 2019-2025 | |
| Biogen, INC. | $995.08 | 2019-2025 | Tysabri, Vumerity, Skyclarys |
| Lilly USA, LLC | $556.14 | 2019-2025 | Kisunla, Amyvid |
| Sk Life Science, INC. | $524.18 | 2021-2025 | Xcopri |
| Lundbeck LLC | $514.06 | 2019-2025 | Vyepti, Rexulti |
| Neurocrine Biosciences, INC. | $482.63 | 2019-2025 | Ingrezza |
| Pfizer INC. | $463.36 | 2023-2025 | |
| Supernus Pharmaceuticals, INC. | $423.38 | 2019-2022 | |
| Genzyme Corporation | $422.37 | 2019-2022 | |
| Celgene Corporation | $319.99 | 2021-2025 | Zeposia |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $266.47 | 2019-2021 | |
| Genentech USA, INC. | $248.20 | 2023-2025 | Enspryng, Ocrevus, Ocrevus Zunovo |
| Acorda Therapeutics, INC | $243.22 | 2019-2023 | Ampyra, Inbrija |
| Otsuka America Pharmaceutical, INC. | $233.05 | 2023-2025 | Rexulti, Nuedexta |
| Amneal Pharmaceuticals LLC | $216.77 | 2019-2024 | Rytary, Ongentys 50mg Capsules 30, Crexont |
| Allergan, INC. | $205.33 | 2019-2022 | |
| Adamas Pharmaceuticals, INC. | $157.04 | 2019-2021 | |
| Abbott Laboratories | $148.56 | 2021-2025 | Infinity |
| Biohaven Pharmaceutical Holding Company LTD. | $129.81 | 2022 | |
| Avanir Pharmaceuticals, INC. | $121.25 | 2019-2022 | |
| Upsher-Smith Laboratories LLC | $114.60 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $114.21 | 2020-2021 | |
| Amgen INC. | $107.02 | 2024-2025 | Uplizna |
| Eisai INC. | $102.45 | 2024-2025 | |
| Argenx US, INC. | $99.74 | 2023-2024 | Vyvgart, Vyvgart Hytrulo |
| Biohaven Pharmaceuticals, INC. | $97.08 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $87.98 | 2019-2023 | Ultomiris |
| Sumitomo Pharma America, INC. | $81.41 | 2023 | Aptiom |
| Harmony Biosciences LLC | $80.79 | 2020-2023 | Wakix |
| Springworks Therapeutics, INC. | $80.56 | 2025 | Gomekli |
| Ucb, INC. | $75.10 | 2019 | |
| Kyowa Kirin, INC. | $64.80 | 2020-2022 | |
| Ge Healthcare | $62.06 | 2020-2025 | |
| Livanova USA, INC. | $56.90 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Neurelis, INC. | $52.25 | 2021 | |
| Averitas Pharma INC. | $41.87 | 2025 | Qutenza |
| Idorsia Pharmaceuticals US INC | $41.82 | 2022-2023 | Quviviq |
| Axsome Therapeutics, INC. | $35.43 | 2025 | Symbravo |
| Boston Scientific Corporation | $26.89 | 2025 | General - Dbs |
| Sanofi-Aventis U.S. LLC | $21.00 | 2019 | |
| Grifols USA, LLC | $20.20 | 2024 | Gamunex-C |
| Alnylam Pharmaceuticals INC. | $13.22 | 2019 | |
| Jazz Pharmaceuticals INC. | $11.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Job Mongare listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.